Goldman Sachs a 'sell' on Valeant — 3 insights

Valeant Pharmaceuticals took another hit after Goldman Sachs issued a 'sell' rating and an $18 price target Jan. 24, Schaeffer's reports.

Here's what you should know:

1. Goldman Sachs cited balance sheet concerns, litigation risks and competition-related pressure as the reason behind the rating.

2. Valeant opened the week at $21.36 Jan. 22, and it was trading at $19.83 as of 1:30 p.m. EST Jan. 24.

3. Valeant hit a 14-month high of $24.45 Jan. 5, but has now dropped below its 10-and 20-day moving averages.

More articles on supply chain:
Congress suspends medical device tax through stopgap spending deal — 6 insights
Cowen: Amazon could leverage Alexa to invade healthcare space
FDA grants IlluminOss marketing clearance for bone stabilization system

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months